Hybrid Nanoplatform: Enabling a Precise Antitumor Strategy via Dual-Modal Imaging-Guided Photodynamic/Chemo-/Immunosynergistic Therapy

• Published in: ACS nano 2021-12, Vol.15 (12), p.20643-20655
• Main Authors: Chen, Haoran, Wu, Fengxia, Xie, Xiaoyu, Wang, Wang, Li, Qiqing, Tu, Langping, Li, Bin, Kong, Xianggui, Chang, Yulei
• Format: Article
• Language: English
• Subjects: Cell Line, Tumor; Doxorubicin - pharmacology; Doxorubicin - therapeutic use; Humans; Nanoparticles; Neoplasms - diagnostic imaging; Neoplasms - drug therapy; Photochemotherapy; Photosensitizing Agents - pharmacology; Photosensitizing Agents - therapeutic use; Theranostic Nanomedicine; Tumor Microenvironment
• ISSN: 1936-0851; 1936-086X
• DOI: 10.1021/acsnano.1c09635

Photodynamic therapy (PDT) has been widely used in tumor therapy due to its high spatial–temporal control and noninvasiveness. However, its clinical application is limited by weak efficacy, shallow tissue penetration, and phototoxicity. Herein, a facile theranostic nanoplatform based on photoswitchable lanthanide-doped nanoparticles was designed. Typically, these nanoparticles had UV–blue and 1525 nm emission upon 980 nm excitation and 1525 nm emission upon 800 nm excitation. We further used these nanoparticles for achieving real-time near-infrared (NIR)-IIb imaging (800 nm) with a high signal-to-noise ratio and imaging-guided PDT (980 nm). Moreover, such a photoswitchable nanoplatform capping with pH-sensitive calcium phosphate for coloading doxorubicin (a chemotherapeutic immunogenic cell death [ICD] inducer) and paramagnetic Mn2+ ions enhances T1-magnetic resonance imaging in the tumor microenvironment. Our results suggest that this theranostic nanoplatform could not only kill tumor cells directly through dual-modal image-guided PDT/chemotherapy but also inhibit distant tumor and lung metastasis through ICD. Therefore, it has great potential for clinical application .